The Mastascope is an ultraslim, hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast. Because many cancers actually begin within an individual milk duct, these intraductal tumors are visualized easily and can be biopsied. This product has been used in leading breast centers in the United Kingdom and other countries with great success. Lifeline has obtained a CE mark for marketing and distribution in Europe.







Lifeline has developed and tested an ultraslim endoscope to directly visualize the ovarian surface in the search for cancer. This is of great advantage to physicians, because neither MRI, X-Ray nor Ultrasonography can provide accurate assessments of subtle surface changes. Initial reports of clinical usage have been encouraging.



About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded. 

Safe Harbor:
This publication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.